Tyrokin 400mg 10pcs(Box)
Tyrokin 400mg 10pcs(Box) Original price was: 3,000.00৳ .Current price is: 2,940.00৳ .
Back to products
Veenat 400mg Tablet 30pcs Box
Veenat 400mg Tablet 30pcs Box Original price was: 4,500.00৳ .Current price is: 3,825.00৳ .
-5%
Click to enlarge

Tyronib 400mg Tablet 10pcs

SKU: 143596

Manufacturer: Healthcare Pharmacuticals Ltd.

Generic: Imatinib

Type: Tablet

Pack Size: 10 Pcs

Apple Shopping Event

Hurry and get discounts on all Apple devices up to 20%

Sale_coupon_15

Original price was: 3,500.00৳ .Current price is: 3,325.00৳ .

Compare
Add to wishlist

Description

  • Imatinib is a small molecule tyrosine kinase inhibitor targeting:
    • Bcr-Abl tyrosine kinase (TK): Key in Philadelphia chromosome-positive leukemias.
    • Receptor TKs: Includes c-Kit (stem cell factor receptor), DDR1/DDR2, CSF-1R, and PDGFR (alpha/beta).
  • Inhibits cellular events mediated by these receptor kinases, controlling malignancy progression.

Absorption and Distribution:

  • Bioavailability: ~98% after oral administration.
  • Time to Peak (Cmax): 2-4 hours post-dose.
  • Steady-State Accumulation: 1.5-2.5x with daily dosing.
  • Protein Binding: ~95%, mostly to albumin and alpha-1 acid glycoprotein.

Metabolism:

  • Primary Enzyme: CYP3A4; minor contributions from CYP1A2, CYP2D6, CYP2C9, and CYP2C19.
  • Main active metabolite: N-demethylated piperazine derivative (CGP74588), similar potency to the parent drug, with 15% AUC of Imatinib.

Excretion:

  • Primary Route: Feces (68% of dose), primarily as metabolites; urine (13%).
  • Elimination Half-Life:
    • Imatinib: ~18 hours.
    • CGP74588: ~40 hours.

Tyronib is indicated for the treatment of:

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+ CML):

  • Newly diagnosed adult and pediatric patients in the chronic phase.
  • Patients in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy.

Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL):

  • Adult patients with relapsed or refractory Ph+ ALL.
  • Pediatric patients with newly diagnosed Ph+ ALL in combination with chemotherapy.

Myelodysplastic/Myeloproliferative Diseases:

  • Adult patients with diseases associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements.

Aggressive Systemic Mastocytosis (ASM):

  • Adult patients without the D816V c-Kit mutation or with unknown c-Kit mutational status.

Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL):

  • Adults with FIP1L1-PDGFRα fusion kinase (confirmed by mutational analysis or FISH demonstrating CHIC2 allele deletion).
  • Patients with HES/CEL with negative or unknown FIP1L1-PDGFRα fusion kinase status.

Dermatofibrosarcoma Protuberans (DFSP):

  • Adult patients with unresectable, recurrent, and/or metastatic DFSP.

Gastrointestinal Stromal Tumors (GIST):

  • Patients with Kit (CD117) positive unresectable and/or metastatic malignant GIST.
  • Adjuvant treatment for adult patients after complete gross resection of Kit (CD117) positive GIST.